BlackRock’s Repare Therapeutics RPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-144,219
| Closed | -$375K | – | 5785 |
|
|
2025
Q4 | $375K | Sell |
144,219
-2,331
| -2% | -$4.69K | ﹤0.01% | 4561 |
|
|
2025
Q3 | $258K | Hold |
146,550
| – | – | ﹤0.01% | 4627 |
|
|
2025
Q2 | $204K | Hold |
146,550
| – | – | ﹤0.01% | 4668 |
|
|
2025
Q1 | $144K | Buy |
146,550
+4,239
| +3% | +$5.11K | ﹤0.01% | 4670 |
|
|
2024
Q4 | $186K | Sell |
142,311
-1,040
| -0.7% | -$3.1K | ﹤0.01% | 4633 |
|
|
2024
Q3 | $493K | Buy |
143,351
+1,548
| +1% | +$5.1K | ﹤0.01% | 4335 |
|
|
2024
Q2 | $468K | Buy |
141,803
+80,538
| +131% | +$287K | ﹤0.01% | 4360 |
|
|
2024
Q1 | $289K | Sell |
61,265
-1,436
| -2% | -$9.2K | ﹤0.01% | 4514 |
|
|
2023
Q4 | $458K | Sell |
62,701
-269,149
| -81% | -$1.51M | ﹤0.01% | 4446 |
|
|
2023
Q3 | $4.01M | Buy |
331,850
+21,965
| +7% | +$227K | ﹤0.01% | 3740 |
|
|
2023
Q2 | $3.28M | Sell |
309,885
-128,632
| -29% | -$1.33M | ﹤0.01% | 3872 |
|
|
2023
Q1 | $4.32M | Sell |
438,517
-19,599
| -4% | -$225K | ﹤0.01% | 3691 |
|
|
2022
Q4 | $6.74M | Buy |
458,116
+47,640
| +12% | +$713K | ﹤0.01% | 3577 |
|
|
2022
Q3 | $4.98M | Sell |
410,476
-2,591
| -0.6% | -$33.4K | ﹤0.01% | 3758 |
|
|
2022
Q2 | $5.78M | Sell |
413,067
-54,244
| -12% | -$639K | ﹤0.01% | 3756 |
|
|
2022
Q1 | $6.66M | Buy |
467,311
+8,680
| +2% | +$129K | ﹤0.01% | 3797 |
|
|
2021
Q4 | $9.67M | Buy |
458,631
+33,594
| +8% | +$791K | ﹤0.01% | 3690 |
|
|
2021
Q3 | $11.2M | Buy |
425,037
+12,589
| +3% | +$407K | ﹤0.01% | 3629 |
|
|
2021
Q2 | $12.9M | Buy |
412,448
+53,847
| +15% | +$1.76M | ﹤0.01% | 3553 |
|
|
2021
Q1 | $11M | Sell |
358,601
-5,354
| -1% | -$182K | ﹤0.01% | 3507 |
|
|
2020
Q4 | $12.5M | Buy |
+363,955
| New | +$10.9M | ﹤0.01% | 3260 |
|
BlackRock's RPTX Position: Q1 2026 in Review
BlackRock sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 144,219 shares — an estimated $375K sold.
BlackRock first reported a position in RPTX in Q4 2020 and held it in 21 quarters. The position peaked at $12.9M in Q2 2021. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.
- BlackRock reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
- BlackRock sold 144,219 Repare Therapeutics shares in Q1 2026, an estimated $375K.
- BlackRock first reported a position in Repare Therapeutics in Q4 2020 and held it in 21 quarters.
- BlackRock's Repare Therapeutics position peaked at $12.9M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.